ArticleiScience2020
A Strategic Target Rescues Trimethoprim Sensitivity in Escherichia coli.
Article in iScience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Overview of the ASM-IISc Symposium on the One Health Approach to AMR in Bengaluru, India.mSphere · 2026Article
- Antibiotic resistance ofOpen veterinary journal · 2025Article
- The role of bacterial metabolism in antimicrobial resistance.Nature reviews. Microbiology · 2025Review
- Article
- Metabolite microextraction on surface-enhanced Raman scattering nanofibres and DNpj biosensing · 2025Article
- Determination of the De Novo Minimum Selection Concentration of Trimethoprim In Vivo forMicroorganisms · 2024Article
- Synthesis of Poly-Lactic Acid by Ring Open Polymerization from Beer Spent Grain for Drug Delivery.Polymers · 2024Article
- Systems-level profiling of early peripheral host-response landscape variations across COVID-19 severity states in an Indian cohort.Genes and immunity · 2023Article
- Identification of Efflux Substrates Using a Riboswitch-Based Reporter in Pseudomonas aeruginosa.mSphere · 2023Article
- Optical photothermal infrared spectroscopy: A novel solution for rapid identification of antimicrobial resistance at the single-cell levelFrontiers in microbiology · 2023Article
- Does Protocatechuic Acid Affect the Activity of Commonly Used Antibiotics and Antifungals?Life (Basel, Switzerland) · 2022Article
- Functional and Biochemical Characterization of the MazEF6 Toxin-Antitoxin System of Mycobacterium tuberculosis.Journal of bacteriology · 2022Article
- Immune Subtyping in Latent Tuberculosis.Frontiers in immunology · 2021Article
- A Multi-Pronged Computational Pipeline for Prioritizing Drug Target Strategies for Latent Tuberculosis.Frontiers in chemistry · 2020Article
- Regulation of translation by one-carbon metabolism in bacteria and eukaryotic organelles.The Journal of biological chemistryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trimethoprim, a preferred treatment for urinary tract infections, is becoming obsolete owing to the rapid dissemination of resistant E. coli. Although direct resistance mechanisms such as overexpression of a mutant FolA and dfr enzymes are well characterized, associated alterations that drive or sustain resistance are unknown. We identify the repertoire of resistance-associated perturbations by constructing and interrogating a transcriptome-integrated functional interactome. From the cross talk between perturbations in stress-response and metabolic pathways, we identify the critical dependence on serine hydroxymethyltransferase (GlyA) as an emergent vulnerability. Through its deletion, we demonstrate that GlyA is necessary to sustain high levels of resistance in both laboratory-evolved resistant E. coli and a multidrug-resistant clinical isolate. Through comparative evolution, we show that the absence of GlyA activity decelerates the acquisition of resistance in E. coli. Put together, our results identify GlyA as a promising target, providing a basis for the rational design of drug combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.